基本信息
views: 20
Career Trajectory
Bio
After his seminal 1972 discovery of the role of complement in the induction of antibody production and related work, Pepys has mostly worked on amyloid and acute phase proteins. He has illuminated the pathogenesis and natural history of systemic amyloidosis, transforming diagnosis of this fatal disease, and improving management and survival. He has also elucidated the structural properties, function and clinical significance of serum amyloid P component (SAP) and C-reactive protein (CRP). He first identified these proteins as therapeutic targets, and has designed and is developing new drugs aimed at them.
His invention of in vivo scintigraphy with radiolabelled SAP enabled systemic amyloidosis for the first time to be safely, non-invasively diagnosed and quantitatively monitored. This revolutionised understanding of the natural history of amyloidosis and its response to therapy, and has guided radical therapeutic developments, focusing attention on the crucial importance of reducing the abundance of amyloid fibril precursor proteins. Pepys has discovered many of the mutations responsible for hereditary amyloidosis, including the first human lysozyme mutation, leading to demonstration that amyloidogenic lysozyme variants are less stable than wild type lysozyme and construction of a widely accepted general model of amyloid fibrillogenesis.
Research Interests
Papers共 585 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Open Biologyno. 12 (2023): 230253-230253
JOURNAL OF INTERNAL MEDICINEno. 6 (2021): 933-935
Mark B. Pepys, Philip N. Hawkins
Oxford University Press eBookspp.C12.12.3-2234, (2020)
Cited0Views0Bibtex
0
0
Mark B. Pepys, Philip N. Hawkins
Oxford Textbook of Medicinepp.2218-2234, (2020)
Oxford Textbook of Medicinepp.2199-2207, (2020)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn